Immunwork

What Immunwork does

Immunwork, Inc. (免疫功坊股份有限公司) is a clinical-stage biotechnology company founded in October 2014 in Taipei, Taiwan, operating as a wholly owned subsidiary of Cayman Islands-incorporated T-E Pharma Holding. The company develops ultra-long-acting drug candidates for endocrine, metabolic, and cardiovascular diseases using its proprietary T-E pharmaceutical technology platform, which combines targeting (T) and effector (E) moieties through novel multi-arm linkers. Its lead technology, the Fatty Acid Bundle platform, conjugates 2-3 fatty acid molecules to therapeutic peptides to enhance serum albumin binding and extend circulation half-life, with sister company T-E Meds (established 2022) extending the platform into antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs) for oncology applications.

The company's clinical pipeline includes TE-8105, a long-acting GLP-1 receptor agonist for type 2 diabetes and obesity that completed Phase 1/2a trials in Australia in 2025; TE-8214, a long-acting octreotide analog for acromegaly and neuroendocrine tumors that completed Phase I in 2025; TE-6168, a thrombolytic fusion protein for ischemic stroke and myocardial infarction; and TE-1146, an ADC for multiple myeloma licensed to Orient EuroPharma. The company has raised approximately USD 45 million across Immunwork funding rounds (2021 Series A and 2022 A-round) plus USD 26 million for T-E Meds, and collected an USD 8.5 million upfront licensing payment from Orient EuroPharma in January 2025.

Immunwork's revenue model is entirely licensing- and partnership-driven, with no commercialized products. The company generates revenue through upfront licensing fees, development milestones, and royalties upon partner commercialization, supported by a partnership ecosystem that includes Orient EuroPharma (commercial licensee for TE-1146), Asymchem Laboratories (CDMO and CRO services), CHO Pharma (CHO-TEM joint technology), and prospective global pharmaceutical partners accessed via industry conferences including BIO Asia-Taiwan, the J.P. Morgan Healthcare Conference, and World ADC conferences. The parent T-E Pharma Holding is targeting a TPEx Emerging Stock Board listing in Q4 2026 to provide a public capital exit while retaining the holding structure.

Name

Immunwork

Legal name

免疫功坊股份有限公司 (Immunwork, Inc.)

Website

https://immunwork.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Immunwork is a clinical-stage Taiwanese biotech developing ultra-long-acting therapeutics for metabolic, endocrine, and cardiovascular diseases using its proprietary multi-arm linker and fatty acid bundle platforms, operating alongside sister company T-E Meds under T-E Pharma Holding.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Ultra-long-acting peptides
• Antibody-drug conjugates
• Fatty acid bundle platform
• Multi-arm linker technology
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Drug Development and Licensing: Pre-revenue clinical-stage biotech company. Revenue expected from out-licensing of drug candidates, milestone payments, and royalties from commercialization. TE-1146 licensing to Orient EuroPharma generated USD 8.5 million upfront.
2. Strategic Partnerships and Collaborations: Co-development arrangements with pharmaceutical partners for T-E product candidates, potentially generating upfront fees, development milestones, and commercialization revenues.
3. Platform Technology Licensing: Licensing of multi-arm linker platforms to design new drugs for various disease indications, generating technology access fees and ongoing collaboration payments.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Immunwork is a clinical-stage biotechnology company developing ultra-long-acting drug candidates using its proprietary T-E (targeting and effector) pharmaceutical platform. The company leverages fatty acid bundle technology to create drug candidates with extended half-lives for metabolic diseases (diabetes, obesity), endocrine disorders (acromegaly, neuroendocrine tumors), and cardiovascular conditions (thrombolytic therapy). Its sister company T-E Meds extends the platform to antibody-drug conjugates (ADCs) and antibody-radionuclide conjugates (ARCs) for oncology indications.

Differentiator

Problem solved

Functional benefit

Products and services

• TE-8105 TE-8105 is a long-acting GLP-1 receptor agonist developed using the fatty acid bundle platform for the treatment of type 2 diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD/NASH). It demonstrated a half-life of 15 hours in mice versus 7.5 hours for semaglutide, enabling potential once-every-two-weeks dosing with superior glucose control and weight loss in preclinical models. Phase 1/2a results showed 5 of 8 participants in B2 cohort achieved >5% body weight reduction.
• TE-8214 TE-8214 is a long-acting octreotide analog developed using the fatty acid bundle platform for the treatment of acromegaly and neuroendocrine tumors (NETs). It features a water-soluble formulation enabling pain-free subcutaneous injection with thin 30G needles versus 19-20G needles for current LAR formulations. Phase I results showed 83% of high-dose participants achieved >20% IGF-1 reduction with no injection site pain or nodules.
• TE-6168 TE-6168 is a novel targeted thrombolytic fusion protein for the treatment of ischemic stroke and myocardial infarction. It demonstrated stronger binding activity to human clots than alteplase, reteplase, and tenecteplase (p<0.0001) with milder internal bleeding side effects. TE-6168 has been designated as a CDE Significant Case by Taiwan's Center for Drug Evaluation.
• Multi-arm Linker Technology Platform The Multi-arm Linker Technology Platform is a proprietary pharmaceutical design system based on novel multi-arm linkers with a core composed of short peptides of natural amino acids and PEGylated amino acids (2-6 EG units), bearing 2+ linking arms and one coupling arm. Functional groups at ends enable conjugation with targeting or effector elements, forming the basis for licensing and co-development partnerships.
• Fatty Acid Bundle Platform The Fatty Acid Bundle Platform uses packed multi-arm linkers carrying 2-3 fatty acid molecules (typically long-chain fatty acids) conjugated at specific amino acid residues (e.g., lysine) or N/C terminals of peptides. This enhances association with serum albumin to prolong circulation half-life, enabling the development of ultra-long-acting drug candidates for endocrine and metabolic diseases.

Quantifiable outcome

• TE-8105 demonstrated half-life of 15 hours in mice, approximately 2x that of semaglutide (7.5 hours)
• +5 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• Asymchem LaboratoriescoreStrategic or Co-development Partner · 24 June 2025T-E Meds and Asymchem signed strategic cooperation agreement for innovative drug development in conjugated therapeutics. Asymchem will leverage T-E Pharma's cytotoxic payload bundle platform to expand ADC capabilities for clients. Scope includes CDMO and clinical CRO services for ADCs and other innovative drug candidates.
• CHO PharmacoreStrategic or Co-development Partner · 1 September 2023T-E Meds and CHO Pharma provide complementary technologies combining CHO Pharma's glycan modification with T-E Meds' Drug Bundles to form a robust ADC development platform. The 'CHO-TEM' technology enables precise site-specific conjugation through straightforward process, creating homogeneous ADCs with high DAR (8 or 12) and dual-payload capabilities.
• T-E Pharma HoldingcoreOthersImmunwork is a wholly owned subsidiary of T-E Pharma Holding (Cayman Island company). T-E Pharma serves as capital and strategic integration platform. Parent company also owns T-E Meds Inc. and is targeting TPEx Emerging Stock Board listing in Q4 2026.
• T-E Meds, Inc.coreOthersT-E Meds is Immunwork's sister company, established in 2022, focusing on ADC and ARC technology platforms and anticancer drug development. While Immunwork develops fatty acid bundle-based drugs, T-E Meds develops antibody-drug conjugates and antibody-radionuclide conjugates using multi-arm linker technologies.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Innovent Biologics: China-based biotech developing biologics including GLP-1 receptor agonists and ADCs. Comparable in clinical-stage pipeline development, multi-modality approach, and Asia-based operations seeking global pharma partnerships.
• Mersana Therapeutics: Clinical-stage biotech developing novel ADCs with proprietary linker platforms (Dolasynthen, Immunosynthen). Comparable as an ADC platform company pursuing differentiated conjugation chemistry and licensing/partnership strategies.
• Tubulis: Germany-based biotech developing next-generation ADCs with proprietary linker technologies enabling differentiated payload conjugation. Comparable as a platform-based ADC developer pursuing licensing deals with major pharma.
• Crinetics Pharmaceuticals: Clinical-stage biotech developing long-acting somatostatin analogs (paltusotine) for acromegaly and NETs - directly competing with TE-8214. Comparable therapeutic focus on ultra-long-acting endocrine peptides.

Broad incumbents

• ImmunoGen (AbbVie): ADC pioneer now part of AbbVie, with multiple approved ADCs (Elahere) and deep pipeline. Comparable as an established ADC platform developer demonstrating scale that newer entrants must compete against.
• Camurus: Sweden-based specialty pharma with FluidCrystal long-acting depot technology for peptides. Comparable expertise in ultra-long-acting injectable peptide formulations serving similar endocrine/metabolic disease markets.

Emerging players

• Sciwind Biosciences: China-based clinical-stage biotech developing long-acting GLP-1 receptor agonists for obesity and metabolic disease. Comparable therapeutic focus to TE-8105 with similar half-life extension strategies.
• Adagene: China/US-based clinical-stage biotech developing ADCs and bispecific antibodies using proprietary antibody engineering platforms. Comparable Asia-based clinical-stage biotech with platform approach to biologic drug development.
• Akeso: China-based biotech with bispecific antibodies and ADCs in clinical development. Comparable Asia-based clinical-stage company developing novel biologics with global pharma licensing strategy.

Others

• WuXi Biologics: China-based global biologics CDMO providing ADC manufacturing and development services. Comparable as an enabler in the ADC ecosystem; Immunwork/T-E Meds partners with CDMOs like Asymchem for similar capabilities.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/immunwork

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunwork